These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18120563)

  • 1. Virulence and tuberculogenic studies of 60 consecutive weekly lots of BCG vaccine produced by standard technique.
    BIRKHAUG K
    Am Rev Tuberc; 1949 May; 59(5):567-88. PubMed ID: 18120563
    [No Abstract]   [Full Text] [Related]  

  • 2. Experiments in BCG standardization three years' experiments on virulence and tuberculogenic potency of lots of BCG vaccine.
    BIRKHAUG K
    Bull World Health Organ; 1952; 5(2):227-44. PubMed ID: 14925821
    [No Abstract]   [Full Text] [Related]  

  • 3. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials.
    Asensio JA; Arbués A; Pérez E; Gicquel B; Martin C
    Expert Opin Biol Ther; 2008 Feb; 8(2):201-11. PubMed ID: 18194076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG Vaccines.
    Tran V; Liu J; Behr MA
    Microbiol Spectr; 2014 Feb; 2(1):MGM2-0028-2013. PubMed ID: 26082111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.
    Marcus SA; Steinberg H; Talaat AM
    Vaccine; 2015 Oct; 33(42):5633-5639. PubMed ID: 26363381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety.
    Chen JM; Islam ST; Ren H; Liu J
    Vaccine; 2007 Nov; 25(48):8114-22. PubMed ID: 17954004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of BCG vaccine strain on the immune response and protection against tuberculosis.
    Ritz N; Hanekom WA; Robins-Browne R; Britton WJ; Curtis N
    FEMS Microbiol Rev; 2008 Aug; 32(5):821-41. PubMed ID: 18616602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
    Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tuberculosis vaccines.
    Martín Montañés C; Gicquel B
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172.
    Wada T; Maruyama F; Iwamoto T; Maeda S; Yamamoto T; Nakagawa I; Yamamoto S; Ohara N
    Sci Rep; 2015 Dec; 5():17827. PubMed ID: 26635118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?
    Martín C
    Eur Respir J; 2005 Jul; 26(1):162-7. PubMed ID: 15994403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.
    de Lisle GW; Wards BJ; Buddle BM; Collins DM
    Tuberculosis (Edinb); 2005; 85(1-2):73-9. PubMed ID: 15687030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis.
    Aguilar LD; Infante E; Bianco MV; Cataldi A; Bigi F; Pando RH
    Vaccine; 2006 Mar; 24(13):2333-42. PubMed ID: 16388878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
    Williams A; Hatch GJ; Clark SO; Gooch KE; Hatch KA; Hall GA; Huygen K; Ottenhoff TH; Franken KL; Andersen P; Doherty TM; Kaufmann SH; Grode L; Seiler P; Martin C; Gicquel B; Cole ST; Brodin P; Pym AS; Dalemans W; Cohen J; Lobet Y; Goonetilleke N; McShane H; Hill A; Parish T; Smith D; Stoker NG; Lowrie DB; Källenius G; Svenson S; Pawlowski A; Blake K; Marsh PD
    Tuberculosis (Edinb); 2005; 85(1-2):29-38. PubMed ID: 15687025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis vaccines: the past, present and future.
    Wang J; Xing Z
    Expert Rev Vaccines; 2002 Oct; 1(3):341-54. PubMed ID: 12901573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoprophylaxis of tuberculosis: an update of emerging trends.
    Singhal N; Bisht D; Joshi B
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):97-106. PubMed ID: 20140756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis: vaccines in the pipeline.
    Ly LH; McMurray DN
    Expert Rev Vaccines; 2008 Jul; 7(5):635-50. PubMed ID: 18564018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.